He completed his undergraduate degree in Chemistry with Pharmacology in 1994 and his Ph.D. in Pharmacology from The University of Liverpool in 1998. After completing a Wellcome Trust Research Career Development Fellowship working alongside Professors Kevin Park (Liverpool) and Werner Pichler (Bern, Switzerland), he joined the Liverpool faculty in 2003. During this time, he helped to develop a new classification system for allergic drug reactions based on the phenotype and function of drug-specific human T-cells. Furthermore, he published several important papers describing mechanisms of drug-specific T-cell activation. Senior Lecturer and Reader status was awarded in 2007 and 2012, respectively.
Recently, Dr Naisbitt has developed practical and conceptual means to combine aspects of genetics, cell biology and chemistry in order to study the fundamental principles of immunological drug reactions. This unique approach has allowed him to study drug hypersensitivity from man to molecule and back again. A deeper understanding of such basic scientific principles can on the one hand inform clinical practice and on the other safe drug development in the Pharmaceutical Industry. He has established sophisticated immunological platforms to study emerging drug safety issues with an immune pathogenesis using HLA-typed lymphocytes isolated from drug-naïve volunteers.
Dr Naisbitt has been recognized with several honours and awards for research. He has been elected to Fellowship of the British Pharmacological Society in recognition of his distinguished service to Pharmacology. Awards of note include the ISSX New Investigator Award (2009), the British Pharmacological Society Novartis prize for excellence in research (2012) and the American Chemical Society CRT Young Investigator Award in 2013. He has been invited to speak at over 50 national or international meetings. He has published more than 110 research articles and has served on the Editorial Advisory Board of Chemical Research in Toxicology.